Wang et al. [118] demonstrated that IL-6R antagonists reduced Th17 cell production mediated by IL-34-stimulated SFs in RA patients, thereby suppressing RA, indirectly suggesting high IL-6R expression in SFs correlates with disease activity. The gene discussed is IL34; the disease is rheumatoid arthritis.